Anil Singhvi shares his view on Mankind Pharma IPO, calls it a stock worth having in portfolio

Market wizard Anil Singhvi recommends going long on Mankind Pharma. It is a stock worth having in your portfolio, he adds.

Anil Singhvi believes Mankind Pharma is a stock worth keeping in the portfolio for the long term.

Zee Business Managing Editor Anil Singhvi suggests investors to buy Mankind Pharma shares from a long-term perspective. Mankind Pharma's IPO, comprising an offer for sale (OFS) worth Rs 4,326 crore, enters the third and final day of the bidding process on Thursday.

How Anil Singhvi rates Mankind Pharma IPO

Singhvi finds the valuation demanded by Mankind Pharma for its IPO a bit expensive. However, he believes Mankind Pharma can make a valuable stock for investors in the long run. Singhvi is of the view that IPOs should be offered at a discount of 15-20 per cent discount to listed players.

"No pharma IPO has made money for investors since November 2021," he pointed out. "If a listing gain occurs, well and good, else focus on investing for the long term... It is a company worth keeping in your portfolio," Singhvi said.

TRENDING NOW

Here are some of the other points that the market wizard made:

Mankind Pharma is a good company with strong fundamentals
It is a debt-free, cash-rich company
It commands a leadership position in most of its products
Its promoters have a solid track record

Mankind Pharma IPO hit the Street on April 25: Issue price, lot size, listing date and more

Important dates: The bidding process will conclude on April 27 — meaning you can bid for the Mankind Pharma IPO until the end of market hours on Thursday.

Mankind Pharma shares are likely to be listed on bourses BSE and NSE on May 8. The initiation of refunds and credit of shares is likely to take place on May 4 and May 5 respectively.

Issue price: Potential investors can bid for Mankind Pharma shares under the IPO in a price band of Rs 1,026-1,080 in multiples of 13, which translates to Rs 13,338-14,040 per lot.

Subscription status: The Mankind Pharma IPO finished the second day of the bidding process with an overall subscription of 87 per cent.

Investor category	Day 2 subscription
Qualified institutional buyer	1.9x
Non-institutional investor	102%
Retail investor	25%
Overall	87%

Catch latest on Mankind Pharma IPO subscription and stock market updates here. For all other news related to business, politics, tech, sports and auto, visit Zeebiz.com.

TAGS: